Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 3,889 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

Translational Development of Photon-counting CT Imaging

NCT03878134
Conditions
Cancer, Inflammatory Disease, Vascular Diseases, Metabolic Bone Disease
Interventions
PHOTON COUNTING CT Scanner
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
Interventions
Cemiplimab, Computed Tomography, Biospecimen Collection, Quality-of-Life Assessment, Magnetic Resonance Imaging, Biopsy, Fianlimab
Biological · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
3
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee
Conditions
Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma
Interventions
Avelumab, M1774
Drug
Lead sponsor
Panagiotis Konstantinopoulos, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Breast Cancer
Interventions
F-18 Fluoroestradiol, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
142
States / cities
Anchorage, Alaska • Bakersfield, California • Irvine, California + 117 more
Conditions
Vaccine Adverse Reaction, Post Acute Covid-19 Vaccination Syndrome
Interventions
Combined metabolic modulator, Rice Protein Powder with Vitamin C
Combination Product · Dietary Supplement
Lead sponsor
Independent Medical Alliance
Other
Eligibility
16 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
ACS - Acute Coronary Syndrome
Interventions
Sponsor MCG deivce
Device
Lead sponsor
SB Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Patient Satisfaction, Conventional Magnetic Resonance Imaging, Portable Magnetic Resonance Imaging
Interventions
Swoop Plus Mk2.0
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Histiocytosis
Interventions
Trail Making Test, Parts A & B, Brief Test of Attention, Symbol Span, Controlled Oral Word Association Test, The Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Hospital Anxiety and Depression Scale, McGill Quality of Life Scale, MR Brain Imaging, Resting state functional MRI, Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 1 more
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Completed No phase listed Observational

3T MRI CIED Post-Approval Study

NCT02969395
Conditions
Cardiac Rhythm Disorder
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
118
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 115 more
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Epcoritamab, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
Reem Karmali
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Safety of a Customized NICU MRI System
Interventions
GE OPTIMA MR430s with HDX/GE Electronics
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Melphalan, Methotrexate, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus, Total-Body Irradiation, Computed Tomography, Echocardiography, Bone Marrow Aspiration and Biopsy, Magnetic Resonance Imaging, Ultrasound Imaging
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Results available

PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer

NCT02287636
Conditions
Childhood Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, magnetic resonance imaging
Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Headache, Tumor, Seizure Disorder, Neurofibromatoses, Hydrocephalus, Abdominal Neoplasm, Spine Deformity
Interventions
propofol, Dexmedetomidine, Glycopyrrolate, Lidocaine 1% Injectable Solution, Nitrous Oxide, Sevoflurane
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Months to 60 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Olaparib, X-Ray Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
Buena Park, California • Los Angeles, California • Newport Beach, California + 10 more
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
454
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 305 more
Conditions
Cervical Dysplasia
Interventions
LuViva Advanced Cervical Scan
Diagnostic Test
Lead sponsor
Guided Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Bay City, Michigan + 1 more
Terminated No phase listed Observational Accepts healthy volunteers Results available

Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening

NCT04877912
Conditions
Breast Cancer
Interventions
MRI Abbreviated Scan, Abbreviated MRI Scan
Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Colorectal Cancer, Neoplasm of Uncertain Malignant Potential
Interventions
DNA methylation analysis, fluorescence in situ hybridization, gene expression analysis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, biopsy, therapeutic conventional surgery, fludeoxyglucose F 18
Genetic · Other · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Propranolol, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia • Buffalo, New York
Conditions
Lymphoma, Diffuse Large B-Cell
Interventions
PNT2258
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more
Conditions
Advanced Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma
Interventions
FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine, Cyclophosphamide, Echocardiography Test, Multigated Acquisition Scan, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biopsy Procedure
Biological · Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Seattle, Washington